Are the Shorts Wrong About InterMune?

In this video entry, David and Austin focus on InterMune, which has shorts pouring in after a tough launch for Esbriet. Is it time to invest in this cutting-edge company on the cheap, or is the poor month a sign of further troubles ahead? Watch and find out.

Many investors are attracted to InterMune and biotechs like it, since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Dave Williamson, Austin Smith, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (3) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 01, 2012, at 5:34 PM, stevewagner wrote:

    The GENERIC Drug Co’s are many P/E, 15 to 20, Mylan at to 18.3 . The large brand drug compan’s J&J, Merk, and Pfizer are at to 16 to 22 (P/E).On Teva (income), analyst 2012 is $5.32 and the trade is out at $39.70 or P/E 7.5. The stock prices , year, then high and low are

    A) 2008 High $50.00, Low $35.89

    B) 2009 High $56.88, Low $41.05

    C) 2010 High $64.95, Low $46.99

    D) 2011 High $57.08, Low $35.00.

    If the Teva will make $5.00 income at P/E 12 = $60 in 2012. If Teva makes $5.60 2013 P/E 15-$84

    At 2016 EPS Teva is going to get $7.29 at P/E 12=$88, or P/E 15=$110.The reason Teva is going to be one of the best stock, there are $78 Billion DRUG PATENT EXPIRATION 2012-2015! Then Teva has 35% of incoming from Brand drugs and big ones coming from Teva and Cephalon!

    This is the most major growth area is (not in the US, which is),its three time more people, it goes into the CHINA, no matter what the economy happens , this will be a high growth about to go!

    I Steve Wagner own options now.

  • Report this Comment On September 01, 2012, at 9:47 PM, stevewagner wrote:

    I Steve Wagner own options now

  • Report this Comment On September 01, 2012, at 9:49 PM, stevewagner wrote:

    On September 01, 2012, at 5:34 PM, stevewagner wrote:

    The GENERIC Drug Co’s are many P/E, 15 to 20, Mylan at to 18.3 . The large brand drug compan’s J&J, Merk, and Pfizer are at to 16 to 22 (P/E).On Teva (income), analyst 2012 is $5.32 and the trade is out at $39.70 or P/E 7.5. The stock prices , year, then high and low are

    A) 2008 High $50.00, Low $35.89

    B) 2009 High $56.88, Low $41.05

    C) 2010 High $64.95, Low $46.99

    D) 2011 High $57.08, Low $35.00.

    If the Teva will make $5.00 income at P/E 12 = $60 in 2012. If Teva makes $5.60 2013 P/E 15-$84

    At 2016 EPS Teva is going to get $7.29 at P/E 12=$88, or P/E 15=$110.The reason Teva is going to be one of the best stock, there are $78 Billion DRUG PATENT EXPIRATION 2012-2015! Then Teva has 35% of incoming from Brand drugs and big ones coming from Teva and Cephalon!

    This is the most major growth area is (not in the US, which is),its three time more people, it goes into the CHINA, no matter what the economy happens , this will be a high growth about to go!

    I Steve Wagner own options now.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2003973, ~/Articles/ArticleHandler.aspx, 8/22/2014 6:05:35 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement